Background: Pulmonary tuberculosis (PTB) is the main apprehension universally. Although treatable, tuberculosis (TB) endures depressingly and disturbs patients’ health-related quality of life (HRQoL) and functioning even after treatment.¹ Resources have revealed that multidrug treatments can lead to unwanted adversative drug reactions such as arthralgia, neurological disorders, hepatotoxicity, and allergic reactions. TB affects the respiratory system, that is, airflow patterns, functional exercise capacity, and ultimately the QoL of patients even after the completion of the 4-month rifapentine-moxifloxacin TB treatment regimen and 6- or 9-month rifapentine, isoniazid, pyrazinamide, and ethambutol (RIPE) TB treatment regimen. Throughout the treatment of active PBT, lung function damage is usually restrictive. Materials and methods: A total of 86 PTB survivors were selected for the PTB survivors’ group, who had a history of taking complete treatment for PTB. Each survivor was evaluated for functional exercise capacity with a 12-minute walk test (MWT), 15-step oximetry test, and HRQoL questionnaire. Results: Pulmonary tuberculosis (PTB) causes variation in vitals and also has negative effects on physical functioning. The study results demonstrated that out of 86 total respondents, the majority (97–100%) had better oxygen levels pretest (12-MWT and pulse oximetry) with an average of 17–20 bpm. 47% of individuals were underweight, with posttest oxygen saturation reduced to 91–93% and respiratory rate increased to 26–30 bpm. QoL was also compromised. Conclusion: This present study concluded that PTBs and their treatment do affect the functional exercise capacity of the survivors. The respiratory rate and blood pressure are markedly increased, whereas the oxygen saturation and manual muscle strength are markedly reduced. PTB survivors also suffered from compromised health and QoL, that is, emotional and mental weaknesses.